Emerging Obesity Research to Watch For in 2025

,

Donna Ryan, MD, highlights exciting advancements in weight loss and metabolic treatments, particularly involving GLP-1 RAs and related therapies.

"What research underway now or planned for 2025 are you and your colleagues most excited about?"

That is a question the editors at Patient Care Online asked renowned obesity researcher and thought leader Donna Ryan, MD, in a recent interview on the latest advances in obesity research. In the video above, Dr Ryan highlights several exciting advancements including a head-to-head comparison of tirzepatide and semaglutide and a phase 2 study on the investigational drug MariTide, which may help preserve lean muscle mass in older adults.

Donna Ryan, MD, is professor emerita at the Pennington Biomedical Research Center in Baton Rouge, LA, and past president of The Obesity Society. She served as associate executive director at Pennington Biomedical for 34 years and her own research encompasses key roles in the DASH (Dietary Approaches to Stop Hypertension), POUNDS Lost, DPP (Diabetes Prevention Program) and Look AHEAD studies. Ryan's continuing research interests focus on translation of effective weight management into primary care practices.

RELATED